目的 探讨降糖宁胶囊联合利拉鲁肽治疗2型糖尿病的临床效果。方法 选取2017年1月—2019年1月张家口市第一医院收治的86例2型糖尿病患者，随机分为对照组和治疗组，每组各43例。对照组皮下注射利拉鲁肽注射液，起始剂量为0.6 mg/次，1次/d，连用1周后以每周增加0.6 mg/d的幅度逐渐调整剂量，直至维持剂量1.8 mg/次，1次/d。治疗组在对照组基础上口服降糖宁胶囊，4粒/次，3次/d。两组均连续治疗12周。观察两组的临床疗效，比较两组治疗前后血糖代谢指标、血脂指标、胰岛功能相关参数、内皮素-1（ET-1）和一氧化氮（NO）的变化情况。结果 治疗后，对照组和治疗组的总有效率分别是81.4%、95.3%，两组比较差异具有统计学意义（P<0.05）。治疗后，两组血清空腹血糖（FPG）、餐后2 h血糖（2h PG）、糖化血红蛋白（HbA1c）水平均较治疗前显著下降，同组治疗前后比较差异有统计学意义（P<0.05）；治疗后，治疗组FPG、2h PG、HbA1c水平低于对照组，两组比较差异具有统计学意义（P<0.05）。治疗后，两组血清三酰甘油（TG）、总胆固醇（TC）及低密度脂蛋白胆固醇（LDL-C）水平均显著降低，而高密度脂蛋白胆固醇（HDL-C）水平显著升高，同组治疗前后比较差异有统计学意义（P<0.05）；治疗后，治疗组TG、TC、LDL-C水平低于对照组，而HDL-C水平高于对照组，两组比较差异有统计学意义（P<0.05）。治疗后，两组血清空腹胰岛素（FINS）、胰岛素抵抗指数（HOMA-IR）、胰高血糖素（GC）、内皮素-1（ET-1）水平均显著减低，而胰岛β细胞功能指数（HOMA-β）、胰岛素敏感性指数（ISI）、一氧化氮（NO）平均显著增高，同组治疗前后比较差异有统计学意义（P<0.05）；治疗后，治疗组FINS、HOMA-IR、GC、ET-1低于对照组，而HOMA-β、ln（ISI）、NO高于对照组，两组比较差异有统计学意义（P<0.05）。结论 降糖宁胶囊联合利拉鲁肽治疗2型糖尿病的整体疗效显著，能有效控制高血糖，纠正血脂代谢紊乱，增强胰岛β细胞功能，提高胰岛素敏感性，保护血管内皮功能，具有一定的临床推广应用价值。

Objective To investigate the clinical effect of Jiangtangning Capsules combined with liraglutide in treatment of type 2 diabetes. Methods 86 Patients with type 2 diabetes in Zhangjiakou First Hospital from January 2017 to January 2019 were randomly divided into control (43 cases) and treatment (43 cases) groups. Patients in the control group were sc administered with Liraglutide Injection, the initial dosage was 0.6 mg/time, once daily; and the dosage was gradually adjusted by increasing 0.6 mg/day per week after 1 week of continuous use until the maintenance dosage was 1.8 mg/time, once daily. Patients in the treatment group were po administered with Jiangtangning Capsules, 4 grains/time, three times daily. Patients in two groups were treated for 12 weeks. After treatment, the clinical efficacy was evaluated, and the changes of glucose metabolism indexes, blood lipid indexes, islet function related parameters, ET-1 and NO in two groups were compared. Results After treatment, the clinical efficacy in the control and treatment groups were 81.4% and 95.3%, respectively, and there were differences between two groups (P<0.05). After treatment, FPG, 2h PG, and HbA1c in two groups were significantly decreased, and there were differences in the same group (P<0.05). After treatment, FPG, 2h PG, and HbA1c in the treatment group were lower than those in the control group, and there were differences between two groups (P<0.05). After treatment, TG, TC, and LDL⁃C in two groups were significantly decreased, but HDL⁃C were significantly increased, and there were differences in the same group (P<0.05). After treatment, TG, TC, and LDL⁃C in the treatment group were lower than those in the control group, but HDL⁃C were higher than those in the control group, and there were differences between two groups (P<0.05). After treatment, FINS, HOMA-IR, and GC and ET-1 in two groups were significantly decreased, but HOMA-β, ISI and NO were significantly increased, and there were differences in the same group (P<0.05). After treatment, FINS, HOMA-IR, and GC in the treatment group were lower than those in the control group, but HOMA-β, ln(ISI) and NO were higher than those in the control group, and there were differences between two groups (P<0.05). Conclusion Jiangtangning Capsules combined with liraglutide has significant effect in treatment of type 2 diabetes, and can effectively control hyperglycemia, correct dyslipidemia, and can enhance pancreatic islet beta cell function, improve insulin sensitivity, and protect vascular endothelial function, which has a certain clinical application value.